Results 1 to 10 of about 267 (98)

国产消炎镇痛药萘普生的药理研究 [PDF]

open access: yesZhongshan Daxue xuebao. Yixue kexue ban, 1980
萘普生(Naproxen)是芳基乙酸类消炎镇痛药。Harrison等曾指出它具有抗炎作用,Roszkowski在动物实验中证明萘普生具有高效的消炎止痛退热作用。Dorfman在该药国际专题讨论会上作了该药动物实验的综述。在临床试用结果亦证明该药对类风湿关节炎、骨关节炎和非关节性风湿病、痛风和一些疼痛具有良好的作用。由于该药疗效好,副作用小,英国已收载于1978年药典。国内广州第八制药厂已合成成功试产。本文主要是就该厂提供的萘普生[d-2-(6’-甲氧基-2’-萘基)丙酸)进行镇痛、消炎、退热等药理研究。
赵香兰
doaj   +2 more sources

Clinical research on progress of antinuclear antibody in rheumatoid arthritis [PDF]

open access: yes, 2023
Rheumatoid arthritis (RA) is a common chronic, systemic autoimmune disease characterized by erosive arthritis, with a global prevalence of 0.25% to 1.00%, which may ultimately lead to joint deformity and loss of function.
LI Yuan, ZHANG Le, YIN Hanlin, ZHENG Bing, LÜ Liangjing
core   +1 more source

Efficacy of Two Drug Regimens in the Treatment of Severe Disease Activity Rheumatoid Arthritis [PDF]

open access: yes, 2017
目的 对重度疾病活动度类风湿关节炎患者用两种药物治疗方案的治疗效果进行探讨分析。方法 随机抽取本院2015年6月—2016年6月收治的40例重度疾病活动度类风湿关节炎的患者作为研究对象,并将其分为对照组和实验组各20例,对照组采用来氟米特联合甲氨蝶呤进行治疗,实验组在此基础上加入沙利度胺进行治疗,对两组的治疗效果进行对比分析。结果 实验组的治疗效果优于对照组的治疗效果,关节肿胀等不良反应均得到了有效的改善,差异具有统计学意义(P〈0.05)。结论 三种药物联合的治疗效果优于两种药物联合的治疗效果 ...
陈煜
core   +1 more source

类风湿关节炎患者康复功能锻炼的研究进展 [PDF]

open access: yes, 2019
类风湿关节炎(Rheumatoid arthritis,RA)是以侵蚀性、对称性多关节炎为主要表现的慢性、全身性自身免疫性疾病, 最终发展为关节畸形和功能丧失, 并损害心、肺、肾、神经等器官[1]。我国RA的发病率为0.32%~0.36%。该病具有病程长、复发率高、致残率高等特点,在临床上又被称为\"不死癌症\"[2],严重危害患者健康。该病治疗的目的是缓解疼痛,提高关节活动度,阻止残疾的发生。康复功能锻炼是降低国家自然科学基金资助项目(编号 ...
刘丽静   +6 more
core   +1 more source

Traditional Chinese Medicine nursing management for rheumatoid arthritis patients with damp-heat arthralgia spasm syndrome (类风湿关节炎湿热痹阻证的中医护理)

open access: yes中西医结合护理, 2021
Objective To explore the effect of Traditional Chinese Medicine (TCM) nursing management for rheumatoid arthritis patients with damp-heat arthralgia spasm syndrome.
LIU Xinying (刘新影)   +3 more
doaj   +1 more source

Research Progress on the Synthesis and Bioactivities of Indole-3-glyoxylamide Derivatives [PDF]

open access: yes, 2017
综述了吲哚-3-乙醛酰胺类化合物(ID)的合成及生物活性的研究进展。ID具有抗肿瘤、抗病毒、抗菌、抗炎、腺苷受体功能调节、缓解疼痛和抗类风湿关节; 炎等多种生物活性,在药物化学领域有广泛应用。ID的合成方法主要为:吲哚母核与乙酰氯在乙醚(或THF)中于室温反应1; h制得含草酰氯结构的中间体;中间体与取代胺基化合物和二异丙基胺乙基胺反应合成ID。并对ID未来的应用作了简要展望。The synthesis and bioactivities of indole-3-glyoxylamide ...
方美娟, 王飞, 胡鸿雨, 赵胜贤
core   +1 more source

Suggestions for Chinese Dietary Lipids Reference Intakes in the New Period [PDF]

open access: yes, 2022
With the rapid development of economy and society, the dietary pattern of Chinese residents has undergone obvious transition. The recommendation of dietary lipids intake has a significant influence on the improvement of dietary pattern and on the ...
JIA Shan-shan, PANG Shao-jie, ZHANG Jian
core   +1 more source

Lenalidomideas a Second-line Therapy Achieves Long-term Remission in Elderly Patients with Relapsed/Refractory Multicentric Castleman's Disease:a Report of Two Cases and Literature Review [PDF]

open access: yes, 2022
No standard therapy is recommended for elderly multicentric Castleman's disease (MCD) patients who failed to the first-line treatment or relapsed. Lenalidomide has been reported to be effective for relapsed/refractory MCD in foreign countries, but ...
TANG Yangming, SHI Renzhou, LAN Mei, LI Xuejun, WEN Zonghua, LU Xiaochen
core   +1 more source

Trial of Chloroquines in the Treatment of COVID-19 and Its Research Progress in Forensic Toxicology [PDF]

open access: yes, 2020
Chloroquines are the long-established prescription drug, which are often used clinically to treat malaria and connective tissue diseases. Since December 2019, corona virus disease 2019 (COVID-19) outbreaks caused by 2019 novel coronavirus (2019-nCoV) has
DUAN Yi-jie*, LIU Qian*, ZHAO Shu-quan, et al.
core   +1 more source

Research progress on perceived risk of patients with rheumatoid arthritis (类风湿性关节炎患者发病风险感知的研究进展)

open access: yes中西医结合护理
Rheumatoid arthritis is an autoimmune disease, and current strategies in the treatment of rheumatoid arthritis (RA) should focus on early identification and diagnosis.
YIN Lingyao (尹凌瑶)   +2 more
doaj   +1 more source

Home - About - Disclaimer - Privacy